Yiwuwar mannose a fannin harhada magunguna ya fi mayar da hankali ne a wasu takamaiman kwatance, wasu daga cikinsu an riga an yi amfani da su a asibiti (kamar rigakafin kamuwa da cutar urinary), yayin da wasu ke cikin bincike na asali ko matakin gwaji na asibiti na farko. Abubuwan da ake sa ran sun cancanci kulawa, amma ana bu?atar ?arin shaida don tallafa musu. Bayyana yuwuwar sa a fagage masu zuwa:

?

1. Gane/Balagagge Filin Aikace-aikace

Hana kamuwa da cutar yoyon fitsari akai-akai (rUTI) ?

Mechanism: Gudanar da mannose na baki yana haifar da babban taro mai yawa a cikin fitsari, tare da gasa tare da toshe ha?in FimH pilin adhesins daga ?wayoyin cuta irin su Escherichia coli zuwa ?wayoyin epithelial na mafitsara, yana hana ?wayoyin cuta yin mallaka kuma fitsari ya wanke su.

Shaida:

Nazarin asibiti da yawa, kamar kwatanta da furotin na ?wayoyin cuta, sun nuna cewa 1.5-2g na mannose a kowace rana yana da tasiri kamar ?ananan ?wayoyin rigakafi don hana rUTI da Escherichia coli ke haifar da mata, kuma yana da ?ananan ha?arin juriya.

?ungiyoyin ?ungiyar ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararrun ?wararru (EAU) sun lissafa shi a matsayin madadin rigakafin rUTI (Level of Evidence: B).

Ab?buwan amf?ni: Babban aminci (launi mai lahani na ciki), babu ha?arin juriya na ?wayoyin cuta mai fa?i.

?ayyadaddun ?ayyadaddun ?ayyadaddun ?ayyadaddun abu kawai don rigakafi kuma ba zai iya maye gurbin maganin rigakafi ba a cikin maganin cututtuka masu tsanani; Tasiri akan marasa Escherichia coli UTI yana iyakance.

2. Yankunan da ke cikin matakin bincike amma tare da bayyananniyar yuwuwar

Maganin Ciwon Glycation na Haihuwa (CDG)

?

Mechanism: Wasu nau'ikan CDG, irin su MPI-CDG (nau'in CDG-Ib), rashin phosphomannose isomerase (PMI), wanda ke hana juyar da mannose-6-phosphate zuwa fructose-6-phosphate, wanda ke haifar da gazawar gabobin jiki da yawa.

Jiyya: Gudanar da baki na mannose na iya ?etare lahani na PMI kuma ya ba da mannose-6-phosphate kai tsaye, yana maido da ha?in glycoprotein.

Halin da ake ciki:

FDA ta amince da amfani da mannose don MPI-CDG, wanda shine ?ayan ?ananan nau'ikan CDG da za a iya magance su.

Mahimman ci gaba a cikin cututtukan hanta, rashin aiki na coagulation, da alamun gastrointestinal, amma ana bu?atar magani na tsawon rai.

Mai yuwuwa: Bincika ?imar warkewar adjuvant don wasu ?ananan nau'ikan CDG, kamar ALG-CDG.

Tsarin rigakafi na Antitumor da isar da magunguna

?

Injiniyanci:

?wararren ?wayar cuta da aka yi niyya: Tumor ala?a macrophages (TAMs) masu kar?an mannose sosai (MRC1), kuma ana iya isar da magungunan mannose ga ciwace-ciwace ta hanyar da aka yi niyya.

Daidaita danne garkuwar jiki: Mannose gasa yana hana masu kar?ar mannose akan saman TAMs, yana toshe fahimtar su na antigens na mannose glycated akan saman ?wayoyin ?ari, wanda zai iya juyar da hana rigakafi.

Ha?aka ilimin chemotherapy: A cikin nazarin dabbobi, ha?in mannose da chemotherapy (irin su doxorubicin) na iya hana ci gaban ?wayar cuta (wata?ila ta hanyar tsoma baki tare da glucose metabolism).

Kalubale: Ana bu?atar ?arin bincike akan tasirin ?an adam, mafi kyawun sashi, da tsarin bayarwa.

Antifungal / antiparasitic kamuwa da cuta adjuvants ??

?

Mechanism: Kwayoyin cuta irin su Candida albicans da Plasmodium sun dogara ga masu kar?ar mannose mai masauki don mamaye sel. Mannose na iya toshe mannewa.

Bincike:

In vitro da nau'ikan dabbobi sun nuna cewa mannose na iya hana Candida adhesion zuwa sel epithelial.

Ha?ewar amfani da magungunan zazzabin cizon sauro na iya rage yawan kamuwa da cutar maleriya (gwajin dabbobi).

Mai yuwuwa: A matsayin adjuvant don ha?aka ingancin magungunan rigakafin da ke akwai da kuma rage juriyar ?wayoyi.

3. Hanyoyi masu tasowa masu tasowa (mai yiwuwa a tabbatar da su)

Cutar kumburin hanji (IBD) da gyara shingen hanji ??

?

Zato:

Mannose na iya daidaita microbiota na gut (yana ha?aka ?wayoyin cuta masu amfani) kuma yana hana mannewar ?wayoyin cuta.

Ha?aka aikin sunadaran shinge na mucosal na hanji ta hanyar gyaran glycosylation.

Halin da ake ciki yanzu: Samfuran dabbobi (colitis) suna nuna wasu tasirin kariya, amma binciken ?an adam ya rasa.

Tsarin cututtuka na autoimmune ??

?

Ka'idar: Glycosylation mara kyau yana da hannu a cikin cututtukan cututtuka na rheumatoid arthritis, lupus, da sauran cututtuka. Kariyar mannose na iya gyara lahani na glycosylation.

Ci gaba: Ana gani kawai a cikin ?irar tantanin halitta ko ?ananan adadin lokuta, ba tare da tsauraran gwaji na asibiti ba.

Rigakafin matsalolin ciwon sukari ??

?

Hankali: Yawan sukarin jini yana haifar da wuce kima marasa enzymatic glycation (AGEs) na sunadaran, yana haifar da rikitarwa. Mannose metabolism ba ya dogara da insulin kuma baya shafar glucose na jini, ko kuma yana iya rage ha?akar AGEs cikin gasa.

Shaida: Gwajin dabbobi sun nuna cewa ci gaban ciwon sukari nephropathy yana raguwa, kuma binciken ?an adam ba shi da komai.

4. Kalubale da iyakoki

Babban kalubale a fagen

Rigakafin UTI ba shi da tasiri a kan ?wayoyin cuta marasa Escherichia coli; Bayanan aminci na dogon lokaci bai isa ba (musamman tasirin aikin koda)

Maganin CDG yana da tasiri kawai ga takamaiman nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in halitta da nau'in nau'in nau'in nau'in halitta da nau'in kwayar halitta da nau'in CD)]. Ana bu?atar ganewar farko da magani na tsawon rai

Ba a san tasirin maganin ?ari a jikin mutum ba; Yawan allurai na iya haifar da gudawa; Ha?arin guba na ha?a chemotherapy yana bu?atar kimantawa

Rashin isassun ingancin amfani guda ?aya na adjuvants na rigakafin cututtuka; Bukatar inganta ha?in gwiwa tare da magungunan da ke akwai

Raunan bincike kan hanyoyin da ke cikin wasu fagage masu tasowa; Rashin ingantaccen gwaji na asibiti; Yawancin su sun kasance a matakin samfurin dabba

5. Jagoran ci gaban gaba

Ha?aka tsarin isarwa daidaitaccen tsari: ?ira mannose gyare-gyaren nanocarriers don ha?aka ?ari/launi mai cutarwa.

Ha?uwa da ha?akawa na farfadowa: bincika tasirin ha?in gwiwar mannose tare da maganin rigakafi, masu hana rigakafin rigakafi, da magungunan rigakafin fungal.

Rare Cuta Fa?awa: Nuna don ?arin nau'ikan CDG da rikice-rikice na ajiyar lysosomal wa?anda za a iya bi da su da mannose.

Tsari mai dorewa-saki mai tsayi: yana magance matsalar yawan magunguna (kamar amfani da yau da kullun don rigakafin UTI).

Dabarun ?ididdige yawan jama'a: daidaitattun magunguna dangane da nau'in pathogen (UTI) ko maye gurbi (CDG)